Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.55 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.55 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.55 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174394 | 0.94 | RAB9A (0.58) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4174162 | 0.93 | FFAR1 (0.54) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4176134 | 0.90 | CA12 (0.53) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4177570 | 0.86 | HPGD (0.49) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4175354 | 0.86 | HPGD (0.49) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4169211 | 0.86 | CNR1 (0.58) | RAB9ANPC1FFAR1 | |
| SCHEMBL4176072 | 0.86 | LMNA (0.55) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4164307 | 0.86 | NPC1 (0.55) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4174490 | 0.84 | FFAR1 (0.50) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4186379 | 0.84 | ALDH1A1 (0.52) | RAB9ANPC1PLAAT3PLAAT5PLAAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | claimed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | FHIT, CYP3A43, DNPEP | RAB9A 4846/4885NPC1 2016/4885PLAAT3 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.